Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf496 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Julius J Schmidt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Cephalosporins, Shock, Septic, Anti-Bacterial Agents, Renal Replacement Therapy. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Shionogi Inc.
Themen: Sepsis
Abstract (Originalsprache)
Objectives
Cefiderocol is a new siderophore cephalosporin for treating severe bacterial infections by Gram-negative pathogens in adults. Significant elimination of the drug will probably occur as a result of kidney replacement therapy, but there are currently insufficient pharmacokinetic data to guide dosing during prolonged intermittent kidney replacement therapy (PIKRT) or the use of the pathogen adsorber Seraph 100. Materials and methods/case reports Pharmacokinetic data were obtained from two critically ill patients undergoing PIKRT and hemoperfusion with the pathogen adsorber Seraph 100. Cefiderocol levels in plasma and dialysate samples were quantified using liquid chromatography with tandem mass spectrometry to evaluate the impact of extracorporeal therapy modalities on cefiderocol pharmacokinetics.
Results
The median cefiderocol dialyser clearance was 80.94 (38.7–87) mL/min, while the Seraph 100 showed no significant clearance [−1.8 (−7.9 to 3.6) mL/min]. The cefiderocol concentration in the total spent dialysate suggests a total elimination of 1350 and 400 mg of cefiderocol, or 68% and 40% of the administered dose.
Conclusion
Cefiderocol is substantially eliminated by PIKRT, but not during hemoperfusion with the Seraph 100. Consequently, dosage adjustments may be necessary depending on the intensity of the PIKRT procedure. Doses used for patients with normal renal function may be required to prevent underdosing during intensive PIKRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
- Medical Clinic V | Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
- Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, Braunschweig, Germany.
- Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
- Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Julius J Schmidt, Jan T Kielstein
Förderung
- Shionogi Inc
Zitieren
APA
Schmidt, J. J., Hagemann, J., Hillebrand, U., Scherneck, S., Sörgel, F., Kinzig, M., & Kielstein, J. T. (2026). Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf496
Vancouver
Schmidt JJ, Hagemann J, Hillebrand U, Scherneck S, Sörgel F, Kinzig M, et al. Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf496
BibTeX
@article{Schmidt2026,
author = {Schmidt, Julius J and Hagemann, Julia and Hillebrand, Uta and Scherneck, Stephan and Sörgel, Fritz and Kinzig, Martina and Kielstein, Jan T},
title = {Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf496}
}
EUVIMED